Effects of Urinary Kallidinogenase combined with Edaravone in treatment of patients with type 2 diabetes mellitus complicated with acute cerebral infarction
Objective:To observe effects of Urinary Kallidinogenase combined with Edaravone in treatment of patients with type 2 diabetes mellitus complicated with acute cerebral infarction.Methods:A prospective study was conducted on 120 patients with type 2 diabetes mellitus complicated with acute cerebral infarction admitted to the hospital from June 2021 to January 2023.According to the random number table method,they were divided into control group and observation group,60 cases in each group.Both groups were given conventional hypoglycemic therapy.On this basis,the control group was treated with Edaravone,while the observation group was treated with Urinary Kallidinogenase on the basis of that of the control group.The clinical efficacy,the glucose and lipid metabolism indexes[fasting blood glucose(FPG),total cholesterol(TC),triglyceride(TG)]levels,the inflammatory factors[interleukin-6(IL-6),soluble vascular cell adhesion molecule-1(sVCAM-1),high-sensitivity C-reactive protein(hs-CRP)]levels,the vascular endothelial indexes[thromboxane B2(TXB2),vascular endothelial growth factor(VEGF),endothelin(ET-1)]levels,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 93.33%,which was higher than 75.00%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of FPG,TC and TG in the two groups were lower than those before the treatment,and those in the observation group were lower than the control group,the differences were statistically significant(P<0.05).The levels of IL-6,sVCAM-1 and hs-CRP in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of TXB2,VEGF and ET-1 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Urinary Kallidinogenase combined with Edaravone in the treatment of the patients with type 2 diabetes mellitus complicated with acute cerebral infarction can improve the clinical efficacy,improve the levels of glucose and lipid metabolism,reduce the inflammatory response,and reduce the levels of vascular endothelial indexes.Moreover,it is superior to single Edaravone treatment.
万方数据
维普
